Current opinion in investigational drugs (London, England : 2000), vol. 7, issue 10 (2006) pp. 924-935
Spherix Inc (formerly Biospherics) is developing tagatose, an orally active lactose derivative for the potential treatment of obesity and type 2 diabetes. The compound is also under investigation for the potential treatment of anemia, hemophilia and medical problems related to infertility, birth weight and excessive maternal food intake. Phase I and II clinical trials have been completed.
Choose a citation style from the tabs below